Table 2 pCR Rates by clinical characteristics
Characteristic | N | non-pCR, n (%) | pCR, n (%) | P-value |
|---|---|---|---|---|
Total | 2334 | 1874 (80.3) | 460 (19.7) | Â |
Age | Â | Â | Â | 0.49 |
  ≤50y | 1415 | 1129 (79.8) | 286 (20.2) |  |
  >50y | 919 | 745 (81.1) | 174 (18.9) |  |
ER | Â | Â | Â | <0.001 |
  Positive | 1365 | 1202 (88.1) | 163 (11.9) |  |
  Negative | 969 | 672 (69.3) | 297 (30.7) |  |
PgR | Â | Â | Â | <0.001 |
  Positive | 1108 | 984 (88.8) | 124 (11.2) |  |
  Negative | 1226 | 890 (72.6) | 336 (27.4) |  |
HER2 | Â | Â | Â | <0.001 |
  Positive | 714 | 521 (73.0) | 193 (27.0) |  |
  Negative | 1620 | 1353 (83.5) | 267 (16.5) |  |
TNBC | Â | Â | Â | <0.001 |
Non-TNBC | 1837 | 1517 (82.6) | 320 (17.4) | Â |
TNBC | 497 | 357 (71.8) | 140 (28.2) | Â |
Tumor size | Â | Â | Â | Â |
  <2 cm | 786 | 596 (75.8) | 190 (24.2) | <0.001 |
  ≥2 cm | 1548 | 1278 (82.6) | 270 (17.4) |  |
Lymph node | Â | Â | Â | Â |
  Positive | 1014 | 892(88.0) | 122 (12.0) | <0.001 |
  Negative | 1314 | 978(74.4) | 336 (25.6) |  |
Nuclear grade | Â | Â | Â | Â |
  1 | 199 | 174 (87.4) | 25 (12.6) | <0.001 |
  2 | 1518 | 1252 (82.5) | 266 (17.5) |  |
  3 | 302 | 184 (60.9) | 118 (39.1) |  |
Histology | Â | Â | Â | 0.60 |
  Ductal | 2064 | 1654 (80.1) | 410 (19.9) |  |
  Others | 270 | 220 (81.5) | 50 (18.5) |  |
CHEK2 H371Y | Â | Â | Â | 0.031 |
  Non-carriers | 2295 | 1848 (80.5) | 447 (19.5) |  |
  Carriers | 39 | 26(66.7) | 13 (33.3) |  |
Chemotherapy type | Â | Â | Â | 0.50 |
  A-based,without a T | 859 | 700 (81.5) | 159 (18.5) |  |
  A-T containing | 882 | 705 (79.9) | 177 (20.1) |  |
  T-based,without a A | 593 | 469 (79.1) | 124 (20.9) |  |
Trastuzumab use | Â | Â | Â | <0.001 |
  Yes | 108 | 61 (57.1) | 47 (43.5) |  |
  No | 2225 | 1812 (81.4) | 413 (18.6) |  |
Surgery type | Â | Â | Â | <0.001 |
  BCS | 983 | 756 (76.9) | 227 (23.1) |  |
  Mastectomy | 1351 | 1118 (82.8) | 233 (17.2) |  |